| Budget Amount *help |
¥2,100,000 (Direct Cost: ¥2,100,000)
Fiscal Year 1996: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 1995: ¥1,100,000 (Direct Cost: ¥1,100,000)
|
|---|
| Research Abstract |
1. We investigated whether irinotecan, a DNA topoisomerase I inhibitor, enhances the radiosensitivity of lung cancer cells in vitro. A small carcinoma cell line (Ms-1) and an adenocarcinoma cell line (Ma-1) were exposed to SN-38, the active metabolite of irinotecan, or cisplatin for 24 h and then irradiated. The effect of each drug plus radiation was evaluated by isobologram method. The combination of SN-38 and radiation had an additive effect on survival of Ma-1 cells and an additive or supra-additive effect on that of Ms-1 cells. The effects of cisplatin combined with radiation were similar. Flowcytometric analysis demonstrated an increase in G2M phase cells rather than S or G1 phase cells following exposure to a low concentration of SN-38.
We conducted the weekly CPT-11 and concurrent TRT in patients with unre sectable stage IIIA and IIIB NSCLC.The objectives of this study were to de termine the maximum tolerated dose (MTD) of CPT-11, when used conven tional 60 Gy TRT.The dose-limiti
… More
ng toxicities were esophagitis, pneumonitis and diarrhea. The MTD was estimated to be 60mg/m2. In this phase I/II study, there were 24 evaluable patients for response, 2 achieved a CR and 16 attained a PR,resulting in over all response rate of 76%.
3. The purpose of study is to identify the risk factors associated with development of pneumonitis following chemoradiotherapy (CRT) . We examined 60 patients (pts) who received CRT from May 1993 to August 1995. There were 17 pts (28.3%) who had >=Grade 2 pulmonary toxicity. Field-size >=200cm^2 tended to be associated with development pneumonitis in the group of all patients (p=0.07). In the concurrent treatment group (38 pts), the incidence of pneumonitis was more frequent (53.8%) in patients with field-size >=200cm^2 than in patients with field-size <200cm^2 (p<0.01). Patients with weekly irinotecan (CPT-11) treatment had pneumonitis more frequently (56.3%) than did those without such treatment (13.6%, p<0.005). When the lower field was included in the radiation site, the incidence of pneumonitis was 70%, compared with 20% for other sites (p<0.01). Multivariate analysis revealed a significant relationship between radiation site and weekly CPT-11 and the risk of pneumonitis (p=0.0096 and p=0.038).Pneumonitis was reversible in all pts but one by steroid therapy. Thus, irradiated site (included lower lung field) and concurrent CRT used with weekly CPT-11 were treatment factors significantly associated with a higher risk of pneumonitis following CRT. Less
|
